Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
291
resultados
Última actualización
15/07/2026 [08:14:00]
Resultados 225 a 250 de 291
Resumen de: US20260146231A1
The disclosure provides a method for producing brain organoids, brain organoids produced by the method, and use of the brain organoids for characterizing the activity of a substance in brain tissue.
Resumen de: WO2026111415A1
The present invention relates to a phosphorylated tau-gold nanoparticle complex, a method for manufacturing the same, and a drug screening method using same. The phosphorylated tau-gold nanoparticle complex manufactured according to the method for manufacturing a phosphorylated tau-gold nanoparticle complex of the present invention enables evaluation of how effectively a specific drug degrades phosphorylated tau aggregates and thus can be advantageously used for high-throughput screening of drugs for preventing or treating primary tauopathies.
Resumen de: WO2026112321A1
The invention relates to a method of detecting ORF2p and/or ORF Ip in a sample comprising: a) enriching ORF2p in the sample; and b) detecting ORFp2 and/or ORF Ip by mass spectrometry. The invention also relates to a method of diagnosing a subject with a disease or disorder (e.g., cancer) comprising detecting ORF2p and/or ORF Ip in a biological sample from the subject, comprising: a) enriching ORF2p in the sample; and b) detecting ORFp2 and/or ORF Ip by mass spectrometry.
Resumen de: WO2026112102A1
The invention relates to systems, methods, and computer-readable media for automated assessment of volumetric changes in brain regions of interest in preclinical animal models. Digital images of brain tissue cross-sections are processed using a convolutional neural network (CNN) to isolate regions of interest, followed by a transformer-based artificial intelligence model utilizing axial and patched attention for pixel classification. Segmentation accuracy is enhanced through a topological data analysis (TDA) algorithm, which refines results by constructing and evaluating simplicial complexes to ensure anatomical continuity. The refined segmentation data is used to calculate three-dimensional volumes based on the Cavalieri principle, and the results are displayed or stored for further analysis. The system offers improved accuracy, efficiency, and consistency over manual methods, supporting preclinical evaluation of therapies targeting neuropathology. Applications include tracking volumetric changes over time and facilitating high-throughput analyses in neurodegenerative disease research.
Resumen de: WO2026110866A1
The present invention addresses the problem of providing, as a means for detecting soluble receptor-type protein tyrosine phosphatase Z (soluble PTPRZ) that can be a biomarker for a glioma, an antibody capable of specifically binding to the soluble PTPRZ. Moreover, the present invention addresses the problem of providing: a novel method for quantifying the protein mass of the soluble PTPRZ; and a standard substance for use in the quantification of said method. Provided is a standard substance for use in quantifying a glycoprotein to which a human natural killer-1 sugar chain (HNK-1 sugar chain) is bound, the standard substance comprising a sugar chain complex including at least two HNK-1 sugar chains.
Resumen de: WO2026108046A1
Provided are a monoclonal antibody against a p-Tau217 protein and the use thereof. Specifically, provided is an antibody targeting a p-Tau217 protein or an antigen-binding fragment thereof. The provided antibody can specifically recognize and bind to a p-Tau217 protein without recognizing p-Tau181 and non-phosphorylated Tau proteins, and can be used in the preparation of a detection preparation or kit for diagnosing diseases associated with the p-Tau217 protein, such as Alzheimer's disease.
Resumen de: US20260146997A1
Idiopathic Parkinson's disease (iPD) is a multi-system disorder, and the debilitating motor stage of iPD can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD) and gastrointestinal symptoms. Widespread immune dysregulation has been reported in clinically diagnosed iPD, but the existence of immune deficits during the prodromal stage has yet to be thoroughly investigated. Here, it was shown that multiple stages of iPD, including the pre-motor prodromal stage, can be stratified according to the immuno-metabolic response to stimulation of peripheral blood immune cells ex vivo. Peripheral blood monocytes from RBD patients displayed increased stimulation-dependent secretion of inflammatory cytokines, including TNF, IL-1β, and IL-8, which peaks in the prodromal stage and successively diminishes as PD progresses. Furthermore, T lymphocyte mitochondrial health was correlated with stimulation-evoked cytokine secretion across patients with RBD, early-stage iPD, and moderate-stage iPD. The results disclosed here have broad implications for mechanistic understanding of how peripheral inflammation may drive disease progression, and it reveals novel biomarkers to enable patient stratification and progression monitoring for clinical trials based on immune endophenotypes.
Resumen de: WO2026112265A1
The presently described and claimed technology relates immunoassay methods of assessing a subject's Alzheimer's Disease status and zygosity for the APOE ε4 allele.
Resumen de: AU2024357691A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
Resumen de: KR20260075695A
본 발명의 PI3K(Phosphoinositide 3-kinase) 억제제를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 약학적 조성물 및 이를 포함하는 파킨슨병의 예방 또는 치료용 약학적 제제와, 후보 약물의 파킨슨병 치료효과를 예측하는 방법에 의하여, 파킨슨병의 치료 및 최적의 치료효과를 갖는 후보 약물의 선정을 기대할 수 있다.
Resumen de: WO2025018933A1
The present embodiments relate to an immunoassay kit capable of measuring p-tau205 in a sample and to methods involving the use of such an immunoassay kit. The present embodiment also relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to p-tau205 and that can be used in such an immunoassay kit.
Resumen de: EP4749281A2
0001 A composition comprising gold nanoparticles which are linked to polyclonal antibodies. The composition may be used to detect the presence of a target which binds to the polyclonal antibody in solution. The binding of the target to the polyclonal antibody triggers a self-assembly of the polyclonal antibody and the gold nanoparticles. This self-assembly of the polyclonal antibody and the gold nanoparticles triggers a colour change in the surface plasmon of the gold nanoparticles which indicates the presence of the target.
Resumen de: EP4748395A1
0001 The present invention relates to the field of biomedicine, in particular, to the use of an intracerebral phosphate homeostasis promoter in cerebral calcification disorders. The intracerebral phosphate homeostasis promoter comprises an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene or an agent targeting astrocytes. In addition, further provided in the present invention are an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene, and the use thereof. Further provided in the present invention are cerebral calcification model based on alternative splicing in an intron of the human SLC20A2 gene, and a preparation method thereof, and the use thereof.
Resumen de: EP4749286A2
The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Resumen de: CN122084910A
本发明公开了一种用于检测β‑淀粉样蛋白42的磁珠‑抗体复合物及其制备方法与应用，用于快速、灵敏、稳定地检测血液中的β‑淀粉样蛋白42。该方法通过系统优化投料比、缓冲液pH、活化时间等关键参数，建立了标准化的偶联工艺，使抗体在磁珠表面的负载量显著提高，并基于此构建了双抗体夹心化学发光检测体系。该试剂盒可在20分钟内完成检测，检测限低至1.6 pg/mL，线性范围为5–1000 pg/mL，批内和批间变异系数（CV）均小于6%，对常见干扰蛋白无交叉反应，在血清中的平均回收率达96.09%，显著提升了Aβ42检测的灵敏度、重复性和准确性，适用于阿尔茨海默病的早期筛查、临床诊断与病情监测。
Resumen de: CN122084904A
本发明公开了一种用于诊断阿尔兹海默症的生物标志物及其筛选方法和应用，涉及阿尔兹海默症生物标志物技术领域，针对阿尔茨海默病缺乏动态病理监测指标、立体异构修饰难以系统性检测的技术问题。本发明首次提出将肽段KLDLSNVQSK和AKTDHGAEIVYK的立体异构修饰水平作为核心生物标志物，其修饰水平与AD的Braak分期显著相关，并提供了包含此标志物的检测方法与联合诊断模型。本发明为AD提供了高相关性、具有动态监测潜力的新型分子靶点，模型诊断精度显著提升，为疾病机制研究、药物开发提供了全新解决方案。
Resumen de: WO2025042955A1
Methods for characterizing disease activity in a systemic lupus erythematosus (SLE) patient. Methods include obtaining a blood, serum, plasma, or urine sample from the patient; assessing the sample for expression of a biomarker selected from the group consisting of IFN-α, IL-10, BLyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10/CXCL10, and IL-4; assessing the sample for expression of an inflammatory mediator selected from the group consisting of TNFRII, Resistin, and Osteopontin (OPN); assessing the sample for an SLE-associated autoantibody specificity biomarker selected from the group consisting of dsDNA, chromatin, RiboP, Ro/SSA, La/SSB, Sm, SmRNP, and RNP; and calculating a Lupus Disease Activity (Immune) Index (LDAII/L-DAI) score. The LDAII/L-DAI score may distinguish between active and low lupus disease activity. Methods of treatment are also provided including administering a treatment prior to reaching clinical disease classification after determining that the patient has the prognosis for transitioning to classified SLE.
Resumen de: WO2025042728A1
The present disclosure relates to murine models of human cancer and autoimmunity and methods of use.
Resumen de: WO2024211135A2
The present invention generally pertains to methods of characterizing crosslinking sites of a protein of interest. In particular, the present invention pertains to the use of size exclusion chromatography, peptide mapping and subunit analysis to identify and quantify crosslinking sites of a protein of interest and determine a contribution of crosslinking to the formation of high molecular weight species.
Resumen de: CN122080559A
0001 本发明公开了一种用于荧光检测的滤光镀膜组合物及其制备方法，涉及光学材料与生物检测技术领域，该组合物通过特定配比的光学功能粉体、高分子基材、分散剂及助剂复配而成，具备高透光率、窄波段选择性、优异的耐候性与机械稳定性，可精准过滤激发光与杂散光，提升荧光检测的灵敏度与特异性。该用于荧光检测的滤光镀膜组合物及其制备方法还提供了该滤光片的制备工艺，操作简便、成本可控，适合规模化生产，尤其适用于基因测序，免疫化学，解决传统滤光片波段选择性差、稳定性弱、成本高的问题，适配阿尔茨海默病生物标志物等荧光检测场景，兼顾精准性、稳定性与经济性，在体外诊断试剂领域具有广阔的应用前景。
Resumen de: WO2021154476A1
Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of making and using the antibodies are also provided.
Resumen de: WO2021019211A1
An elution buffer for eluting one or more predetermined analytes from one or more analyte-specific antibodies or fragments thereof or for eluting one or more predetermined antibodies or fragments from a target antigen, wherein: the elution buffer has a pH of 1 to 5; and the elution buffer comprises a predetermined amount of an acid stable mass spectrometry ionisation control protein. The use of the elution buffer in the detection and quantifying of analytes, for example by mass spectrometry is also described.
Resumen de: WO2025075789A1
Human tau protein phosphorylated at the amino acid, serine 413 (pS413 tau), can serve as a biomarker for tauopathies such as Alzheimer's disease. Detection and quantitation of pS413 tau in a biological sample such as cerebrospinal fluid can be useful in developing therapeutics for certain tauopathies. However, pS413 tau is present in biological samples at very low levels. Thus, the invention provides a highly sensitive assay for the detection and quantitation of pS413 tau in a biological sample comprising a series of steps as described herein.
Resumen de: WO2025078596A1
The present invention provides a non-invasive, ex vivo method for diagnosing, prognosing or monitoring Parkinson's disease (PD) in a subject, the method comprising determining the ratio of CD8 terminally- differentiated effector T cells (CD8 TEMRA) to CD8 central memory T cells (CD8 TCM) in a biological sample from the subject, and computer program products for carrying out the method. Also provided herein is a kit, in particular a kit for diagnosing, prognosing or monitoring PD, the kit comprising: (a) means specifically adapted for determining the ratio of CD8 TEMRA to CD8 TCM; and (b) optionally a reference for said ratio or means for establishing said reference, wherein said reference represents a known diagnosis or prognosis of PD, wherein (a) and optionally (b) are the only biological reagents present in said kit, and uses thereof.
Nº publicación: JP2026086590A 26/05/2026
Solicitante:
シーダーズ―シナイメディカルセンター
Resumen de: WO2019160978A1
Methods and systems for diagnosing, providing prophylaxis, and treating one or more age-related neurodegeneration or pathological cognitive impairment are provided. Provided are methods to protect against and/or reduce the severity of cognitive decline in an at risk elderly subject, a mild cognitive impaired subject, and/or a subject with neurodegenerative disease, comprising administering an inhibitor of CD103, an inhibitor of the effector molecules of CD8+ resident memory T cells, and/or a tolerogenic vaccine. Provided is a method for identifying subjects susceptible to or experiencing age-related neurodegeneration, comprising detecting increased levels of CD103+ resident memory T cells. A kit is provided for collecting and quantifying CD103+ CD8+ resident memory T cells.
BOPI
Sede Electrónica
